Xilio Therapeutics Inc (NAS:XLO)
$ 1.315 -0.125 (-8.68%) Market Cap: 57.80 Mil Enterprise Value: -3.19 Mil PE Ratio: 0 PB Ratio: 1.73 GF Score: 34/100

Xilio Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2022 / 06:55PM GMT
Release Date Price: $2.4 (-8.40%)
Michael Eric Ulz
Morgan Stanley, Research Division - Equity Analyst

Good afternoon, everyone, and thanks for joining us for the Morgan Stanley Global Healthcare Conference. I'm Mike Ulz, one of the biotech analyst here. And it's my pleasure to introduce Marty Huber, President from Xilio Therapeutics.

Just a reminder, the format for today is a fireside chat. But before we get into Q&A, I need to read a quick disclaimer. So for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

Questions & Answers

Michael Eric Ulz
Morgan Stanley, Research Division - Equity Analyst

And with that, Marty, thanks for being here. And maybe just to start off, since not everyone might be familiar with your platform, if you can talk about GPS or your geographically precise solutions, and how that actually works.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot